01—Abstract
Summary
Summary of the 10-Q filed May 6, 2026. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reported first-quarter 2026 consolidated net income of $468.3 milliona, up from $434.4 million in the prior-year period, and net income attributable to Royalty Pharma plc of $294.7 million versus $239.3 million.
Diluted EPS was $0.67b compared with $0.55. Total income and other revenues rose to $630.6 million from $568.2 million, led by income from financial royalty assets of $595.0 million. Results were partly offset by a $69.4 million non-cash financial royalty asset impairment related to Tazverik, following its voluntary withdrawal, and by general and administrative expenses that rose to $159.5 million, driven by share-based compensation of $122.3 million tied to the Internalization.
The filing also recorded a $197.5 millionc provision income from changes in expected cash flows and credit losses. Cash flow from operations was $718.2 million, up from $596.1 million. Portfolio Receipts were $925.4 million versus $839.3 million, and Portfolio Cash Flow was $722.1 million versus $610.8 million (non-GAAP).
The company invested $527.9 milliond in royalties, milestones and other contractual receipts, including acquisitions of financial royalty assets of $452.4 million in the cash flow statement. It repurchased 1.1 million Class A shares for about $50.1 million, leaving approximately $1.7 billion under the repurchase program, and paid a $0.235 per share quarterly dividend totaling $104.5 million. Total debt principal was $9.2 billion at March 31, 2026, including a $380 million term loan maturing July 31, 2026.
Cash and cash equivalents were $586.4 million. The filing notes that Vertex's Alyftrek royalty payments are in a dispute resolution process, and that Revolution Medicines' second $250 million royalty tranche was funded on May 4, 2026, following positive Phase 3 results.
02—Key points
Key Highlights
- Net income attributable to Royalty Pharma plc rose to $294.7 million ($0.67 diluted EPS) from $239.3 million ($0.55) a year earlier.
- Total income and other revenues increased 11.0% to $630.6 million, with income from financial royalty assets up 10.3% to $595.0 million.
- Portfolio Receipts increased 10.3% to $925.4 million; Royalty Receipts rose 12.5% to $887.2 million, led by Tremfya, Evrysdi and Voranigo.
- A $69.4 million non-cash impairment was recorded on Tazverik after Ipsen and Eisai announced its withdrawal in March 2026.
- General and administrative expenses rose 44.1% to $159.5 million, mainly from share-based compensation of $122.3 million following the Internalization.
- Operating cash flow was $718.2 million, and the company invested $527.9 million in new royalties, milestones and other contractual receipts in the quarter.
- Cash and equivalents were $586.4 million and total debt principal was $9.2 billion; a $380 million term loan matures July 31, 2026.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed May 6, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $630.58M$568.25M | +11.0% |
| R&D Expenses | $39.79M$50.50M | −21.2% |
| Operating Expenses | $67.54M$34.06M | +98.3% |
| Operating Income | $563.04M$534.18M | +5.4% |
| Net Income | $294.69M$239.35M | +23.1% |
| EPS (Basic) | $0.67$0.55 | +21.8% |
| EPS (Diluted) | $0.67$0.55 | +21.8% |
| Shares Outstanding (Basic) | 436.79M435.48M | +0.3% |
| Shares Outstanding (Diluted) | 556.84M578.10M | −3.7% |
05—Questions
Frequently Asked Questions
What drove the increase in net income attributable to Royalty Pharma plc?
Net income attributable to Royalty Pharma plc rose to $294.7 million from $239.3 million. Consolidated net income increased to $468.3 million from $434.4 million, driven by higher income from financial royalty assets and a $197.5 million provision income, partly offset by the Tazverik impairment and higher G&A expenses. Net income attributable to non-controlling interests fell to $173.6 million from $195.1 million.
How did the Tazverik withdrawal affect results?
Following Ipsen's and Eisai's March 2026 announcements of Tazverik's voluntary withdrawal, the company recorded a $69.4 million non-cash financial royalty asset impairment in the first quarter of 2026. The filing states that the impairment reduced net income attributable to Legacy Investors Partnerships, which contributed to the $13.6 million decrease in their share of net income.
What is the status of the Vertex Alyftrek royalty dispute?
Beginning in the second quarter of 2025, Royalty Pharma did not receive the full amount of royalty receipts on Alyftrek net sales that it believes it is contractually entitled to. It has commenced dispute resolution procedures. Any amounts receivable will be recognized only upon resolution of the matter in its favor.
How much capital did the company deploy and return to shareholders this quarter?
The company invested $527.9 million in royalties, milestones and other contractual receipts. It paid $104.5 million in dividends to Class A shareholders and repurchased Class A shares for $50.1 million, leaving approximately $1.7 billion available under its $3.0 billion repurchase program.
What upcoming debt and funding obligations should investors monitor?
The $380 million term loan matures July 31, 2026, and the filing lists $380 million of principal payments for the remainder of 2026. As of March 31, 2026, $1.75 billion of the Revolution Medicines funding commitment and $500 million of the Johnson & Johnson JNJ-4804 arrangement remained unfunded, and $175 million remained available under Cytokinetics Funding Commitments. Revolution Medicines' second $250 million royalty tranche was funded on May 4, 2026.
06—Continue